Farringdon Capital Ltd. Takes $250,000 Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Farringdon Capital Ltd. acquired a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,198 shares of the company’s stock, valued at approximately $250,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC lifted its stake in shares of Prestige Consumer Healthcare by 3.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock worth $126,274,000 after acquiring an additional 49,331 shares during the period. Geode Capital Management LLC lifted its position in Prestige Consumer Healthcare by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company’s stock worth $105,342,000 after purchasing an additional 21,951 shares during the period. Invesco Ltd. lifted its position in Prestige Consumer Healthcare by 2.4% in the fourth quarter. Invesco Ltd. now owns 1,060,263 shares of the company’s stock worth $82,796,000 after purchasing an additional 24,392 shares during the period. Congress Asset Management Co. boosted its stake in Prestige Consumer Healthcare by 5.0% during the 4th quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock valued at $70,964,000 after purchasing an additional 43,619 shares in the last quarter. Finally, Boston Trust Walden Corp increased its position in shares of Prestige Consumer Healthcare by 43.5% during the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock valued at $64,942,000 after purchasing an additional 252,089 shares during the period. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Up 0.4 %

Shares of NYSE:PBH opened at $80.10 on Friday. The firm has a 50 day simple moving average of $84.16 and a 200 day simple moving average of $80.16. Prestige Consumer Healthcare Inc. has a 52 week low of $62.35 and a 52 week high of $90.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The company has a market cap of $3.97 billion, a PE ratio of 18.76, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on PBH shares. DA Davidson raised their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Canaccord Genuity Group raised their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, February 7th. StockNews.com downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Tuesday, April 8th. Oppenheimer raised their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. Finally, Royal Bank of Canada lifted their price target on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a “sector perform” rating in a research report on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Hold” and an average target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.